Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty
Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties
Hold Rating on Synlogic Amidst Lead Program Discontinuation and Strategic Uncertainties
Synlogic Analyst Ratings
H.C. Wainwright Upgrades Synlogic (SYBX) to a Hold
Hold Rating on Synlogic Amid Discontinued Lead Program and Reduced Price Target
Synlogic Shares Downgraded After Trial Discontinuation
Synlogic Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Fusion Pharmaceuticals (FUSN), Enanta Pharmaceuticals (ENTA) and Synlogic (SYBX)
Synlogic Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Harrow Health (HROW), Synlogic (SYBX)
Progressive Synpheny-3 Trial and Extended Patent Protection Propel Buy Rating for Synlogic
Synlogic's Financial Strength and Promising Clinical Trials Bolster Buy Rating
Chardan Capital Reiterates Buy on Synlogic, Maintains $6 Price Target
Synlogic Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: BioLife Solutions (BLFS), Synlogic (SYBX)
Synlogic Analyst Ratings
Synlogic (SYBX) Receives a Buy From H.C. Wainwright
The Latest Analyst Ratings for Synlogic
Synlogic Analyst Ratings
No Data
No Data